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ABSTRACT 
Many prostate cancer (PCa) recurrences are thought to be due to reactivation of 
disseminated tumor cells (DTCs). We previously found a role of the TAM family of 
receptor tyrosine kinases TYRO3, AXL and MERTK in PCa dormancy regulation. 
However, the mechanism and contributions of the individual TAM receptors is largely 
unknown. Knockdown of MERTK, but not AXL or TYRO3 by shRNA in PCa cells 
induced a decreased ratio of P-Erk1/2 to P-p38, increased expression of p27, NR2F1, 
SOX2, and NANOG, induced higher levels of histone H3K9me3 and H3K27me3, and 
induced a G1/G0 arrest, all of which are associated with dormancy. Similar effects were 
also observed with siRNA. Most importantly, knock down of MERTK in PCa cells 
increased metastasis free survival in an intra-cardiac injection mouse xenograft model. 
MERTK knockdown also failed to inhibit PCa growth in vitro and subcutaneous growth 
in vivo, which suggests that MERTK has specificity for dormancy regulation or requires a 
signal from the PCa microenvironment. The effects of MERTK on the cell cycle and 
histone methylation were reversed by p38 inhibitor SB203580, which indicates the 
importance of MAP kinases for MERTK dormancy regulation. Overall, this study shows 
that MERTK stimulates prostate cancer dormancy escape through a MAP kinase 
dependent mechanism, also involving p27, pluripotency transcription factors, and histone 
methylation. 
  
Prostate cancer patients often have long time periods between curative intent surgery or 
radiation therapy until the time of biochemical recurrence or metastatic disease visible 
with current imaging, which marks incurable disease with current treatment options. For 
example, in a large series of patients treated with radical prostatectomy, nearly 20% 
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recurrences occurred at least 5 years after surgery(Amling, Blute et al. 2000). Greater 
than half of prostate cancer patients with no evidence of disease soon after radical 
prostatectomy were found to have disseminated prostate tumor cells (DTCs) in their bone 
marrow, which are thought to be a major source of distant recurrences(Morgan, Lange et 
al. 2009). This finding implies that many of these tumor cells die, never grow, or grow 
very slowly. Many investigators refer to this ability of cancer cells to remain viable but 
not have detectable growth as “cellular dormancy.” 
 
There is significant interest in regulators of cancer cellular dormancy. Several studies 
have identified a low ratio of phosphorylated MAPK3/MAPK1 (Erk 1/2) to 
phosphorylated MAPK14 (p38) as marking dormant tumor cells. TGFB2 (TGF-β2) 
was proposed to be the major ligand responsible for dormant behavior of head and 
neck squamous cell carcinoma cells. The cell cycle inhibitor CDKN1B (p27) and 
transcription factor BHLHE41 (DEC2) were implicated as nuclear signals(Bragado, 
Estrada et al. 2013). More recently, pluripotency associated transcription factors 
NR2F1, SOX2, SOX9, NANOG, and RARB were identified as transcriptional 
regulators of dormancy in head and neck, prostate and breast cancers(Sosa, Parikh et 
al. 2015). Similarly, others have shown that TGF-β family member BMP7 maintains 
prostate cancer dormancy through autocrine SPARC(Sharma, Xing et al. 2016) 
(Kobayashi, Okuda et al. 2011). A role of the epigenome in regulating cellular 
dormancy is also becoming apparent. Histone H3 tri-methylated lysine 9 and tri-
methylated lysine 27 were shown to identify and to be important for dormant cells, 
primarily in head and neck cancer(Sosa, Parikh et al. 2015).   
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Our group has established a role of the TYRO3, AXL and MERTK (TAM) family of 
receptors and one of their ligands, growth arrest-specific 6 (GAS6), in regulation of 
prostate cancer cell dormancy in the bone marrow(Shiozawa, Pedersen et al. 2010, 
Jung, Shiozawa et al. 2012, Taichman, Patel et al. 2013). We also found that GAS6 and 
MERTK are important for cancer stem like cell formation (Jung, Decker et al. 2016, 
Shiozawa, Berry et al. 2016). This receptor family has an established role in the 
regulation of the innate immune system, but more recently has been shown to be 
important for cancer growth and metastasis as well. For example, MERTK was 
recently identified in a screen of wild type kinases as a mediator of prostate cancer 
metastasis(Faltermeier, Drake et al. 2015). The TAM family of receptors have a high 
degree of homology, but have been shown to have different functions, which might 
relate to differences in ligand binding affinities and downstream pathways(Graham, 
DeRyckere et al. 2014). There are at least four vitamin K dependent γ–carboxyalated 
protein ligands that bind at least one of the TAM receptors including GAS6, PROS1 
(Protein S), TUB (tubby), and TULP1 (tubby like protein 1)(Caberoy, Zhou et al. 
2010). We found that GAS6 decreased prostate cancer proliferation and protected the 
cells from chemotherapy induced apoptosis(Shiozawa, Pedersen et al. 2010, Lee, 
Decker et al. 2016). We also found that prostate cancer bone metastases grew larger in 
the absence of GAS6 in a bone(Jung, Shiozawa et al. 2012).  
 
However, these studies did not identify which of the TAM receptors are responsible for 
the ability of GAS6 to slow prostate cancer growth, while also preventing apoptosis – 
findings which are consistent with cellular dormancy. However, the role of TYRO3 
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and MERTK remained unclear. To begin to answer this question, we previously 
studied the relative expression level TYRO3 and AXL in prostate cancer primary 
tumors, DTCs and in gross metastases. However, MERTK was not included in these 
studies. We found that TYRO3 was expressed highly in the primary tumors but that 
AXL was expressed highly in disseminated but dormant disease(Taichman, Patel et al. 
2013). Based on these results, we hypothesized that TYRO3 might play a role when 
prostate cancer was actively growing but that AXL might play a role when it is 
dormant. However, these studies did not include experiments to test this hypothesis 
further than gene expression. Most recently, in work that is currently in press, we 
reported that AXL is required for TGF2 to induce prostate cancer dormancy(Yumoto 
2016). However, the contributions of MERTK and TYRO3 remain unclear.   
 
In the current study we took an unbiased approach to discern which of the TAM 
receptors, including MERTK, are required for prostate cancer dormancy escape. With 
shRNA and siRNA technology, we knocked down the expression of each of the three 
receptors in three different prostate cancer cell lines. We found that loss of MERTK, 
but not the other receptors decreased the ratio of P-Erk to P-p38, increased the 
expression of p27 and pluripotency associated transcription factors, increased the 
levels of dormancy associated histone H3 marks and caused accumulation of cells in 
the G1 and G0 phases of the cell cycle, and decreased apoptosis, all of which 
characterize dormant cells. Importantly the effect of MERTK on the cell cycle and 
histone H3 post-translational modifications was reversed by altering MAP kinase 
signaling with a p38 inhibitor. We also found that MERTK knockdown increased 
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metastasis free survival in an intra-cardiac injection mouse prostate cancer xenograft 
model, but did not inhibit in vitro cell growth or subcutaneous tumor growth showing 
that it did not compromise global growth characteristics. Thus, our studies implicate 
MERTK in stimulation of prostate cancer dormancy escape by a mechanism particular 
to the metastatic microenvironment and involving MAP kinases.   
 
MATERIALS AND METHODS 
 
Cell culture 
Human PCa cell lines, PC3, Du145, and LNCaP C4-2B (C4-2B) were obtained from 
American Type Culture Collection (Rockville, MD (PC3 and Du145)) and UroCor 
(Oklahoma City, OK (C4-2B)). PCa cells were maintained in RPMI 1640 with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (P/S) in a humidified incubator with 
5% CO2. For in vitro assays, unless indicated otherwise, cells were seeded at a density 1 
x 105 / ml, allowed to rest for one day in 10% serum and then changed to reduced serum 
concentrations as indicated. For the p38 inhibitor experiments, cells were first cultured 
for 14 days under routine conditions with 10% serum and 5 µM SB203580 (EMD 
Millipore #A8254) dissolved in DMSO or 0.05% DMSO control. 
 
TAM receptor stable shRNA knockdowns 
GFP and luciferase expressing PCa cell lines (PC3GFP, Du145GFP, and C4-2B GFP cells) 
were first established by lentiviral transduction. Stable knockdowns of the TAM 
receptors (TYRO3, AXL and MERTK) were then generated by lentiviral infection. 
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Lentiviruses were constructed by the University of Michigan Vector Core using pGIPZ 
lentiviral vectors containing either a shRNA targeting one of the TAM receptors or a 
nonsilencing (shControl) shRNA (Open Biosystems). Stable lines were selected with 
puromycin. Knockdown of greater than 80% was verified by Western blotting and qRT-
PCR. qRT-PCR gene expression data is presented as mean ± SEM of independent 
cultures.  
MerTK transient siRNA knockdowns 
siRNAs targeting MerTK (# s20474, s20473 and s20472) and control siRNA (siControl) 
(# 4390843) were purchased from Thermo-Fisher Scientific. Transient transfection in C4-
2B and PC3 cells was performed using 10 mM of each siRNA with Lipofectamine 
RNAiMAX reagent (Thermo-Fisher) using the reverse transfection protocol, followed by 
three days incubation. Knockdown was verified by real time qRT-PCR. Data is presented 
as mean ± SEM of triplicate PCR reactions.   
 
Western blotting  
Cells were serum starved overnight unless indicated otherwise. Lysates were prepared in 
cOmplete lysis M (Roche #04 719 956 001) supplemented with proteinase inhibitor Mini 
cOmplete Tablets (Roche #04705378) and phosphatase inhibitor PhosSTOP EASYpack 
Tablets (Roche #04 906 837 001). Protein concentration was determined by the BCA 
method. 20 µg of total protein was added per lane of 4-20% reducing SDS 
polyacrylamide Tris-Glycine gels after sample preparation in Laemmli sample buffer. 
The samples were transferred to PVDF membranes and blocked for 1 hour in 5% dry 
milk in TBS with 0.1% Tween-20 (TBST). Antibodies for phosphorylated proteins were 
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applied at 4˚C overnight in 5% BSA TBST, washed and visualized with a horseradish 
peroxidase conjugated anti-rabbit IgG secondary antibody (Cell Signalling #7074S) and 
SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific #34075). Images 
were acquired with a ChemiDoc Touch imager (BioRad). Membranes were stripped with 
Restore PLUS stripping buffer (Thermo Scientific #46430). They were blocked and re-
probed for antibodies to total proteins, and again striped and re-probed for GAPDH or β-
actin to normalize for protein loading. All primary antibodies were monoclonal rabbit 
from Cell Signaling Technology. Catalog numbers and dilutions were as follows; 
Phosphorylated-Erk 1/2 (P-Erk) Y204(#4377S, diluted 1:500), total Erk (#4695, 1:500), 
Phospho-p38 (P-p38) T190/Y182 (#4511, 1:500), total p38, (#9212, total Axl (#4939, 
1:500), total Tyro3 (#5585, 1:500), total MerTK (#4319, 1:500), Sox2 (# 3579, 1:500), 
Caspase-9 (#9502, 1:1000), β-actin (#4970, 1:2000), and GAPDH (#2118, 1:2000). 
Images representative of biological replicates are shown and cropped for presentation. 
For P-Erk, P-p38, and p27 quantification, images from five independent experiments 
were quantified relative to each vehicle treated scrambled shRNA control with BioRad 
ImageLab software and then normalized to housekeeping gene expression. The P-Erk to 
P-p38 ratio was obtained by dividing the normalized P-Erk and P-p38 values for each 
independent experiment. All data are shown as fold change from control.   
 
Real time reverse transcriptase PCR (qRT-PCR) 
Cells were lysed and RNA was harvested using the Qiagen RNeasy kit followed by 
reverse transcription using Invitrogen SuperScript II Reverse Transcriptase. Real time 
qPCR was performed using TaqMan Universal PCR Master Mix and Gene Expression 
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Assays on a Applied Biosystems ViiA 7 instrument. TaqMan MGB probes (Applied 
Biosystems) were as follows: MERTK (Hs00179024_m1), p27 / CDKN1B (Hs00153277), 
SOX2 (Hs01053049_s1) and NANOG (Hs02387400). We designed primers and a probe 
to specifically detect NR2F1 / TFCOUP1: forward; CAAAGCCATCGTGCTGTTCAC, 
reverse; CCTGCAGGCTCTCGATGT, and probe; TCAGACGCCTGTGGCCTG. β-
actin (Hs01060665_g1) was used as an internal control for the normalization of target 
gene expression.       
 
Flow cytometry for histone post-translational modifications and Ki67.  
Cell pellets were fixed and permeabilized with dropwise addition of 1 ml of cold 70% 
ethanol and then incubated overnight. All steps were at 4ºC or on ice. Samples were then 
washed, blocked and incubated for one hour in flow buffer (PBS with 2% FBS and 2 mM 
EDTA) with each of the following antibodies; Alexa 647 conjugated rabbit anti histone 
H3 tri-methylated lysine 27 diluted 1:50 (Cell Signaling Technology #12158), 
unconjugated rabbit polyclonal anti histone H3 tri-methylated lysine 9 (Abcam #8898) , 
or APC conjugated rabbit anti-human Ki-67 antibody (Biolegend #350513). Cells were 
washed twice with flow buffer. The unconjugated histone H3 tri-methylated lysine 9 
antibody was detected with an Alexa 647 conjugated anti-rabbit IgG diluted 1:250 (Cell 
Signaling Technology #4414). Data was acquired with a three laser (405 nm, 488 nm and 
640 nm) Becton Dickinson FACS Aria IIu flow cytometer. Gating was forward scatter vs 
side scatter, single cells (linear on FSC-A vs FSC-H), then the 670/30 filter (APC or 
Alexa 647) vs forward scatter or histogram. An isotype control antibody was used for 
setting the gates. Negative and dim cells were selected for methylated histones. Negative 
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cells were selected for Ki67. Data is presented as representative plots or mean ± SEM of 
triplicate wells from replicate experiments.  
 
Cell cycle analysis 
Cells were cultured for three days as indicated and pulsed with 10 µM 
bromodeoxyuridine (BrdU) for 30 minutes. The cells were collected with trypsin as 
necessary and then fixed and stained for total DNA with 7-AAD and BrdU incorporated 
into DNA using the Becton Dickinson APC BrdU flow kit (#552598). Data was acquired 
with a Becton Dickinson FACS Aria IIu flow cytometer. Gating was forward scatter vs 
side scatter, single cells (linear on FSC-A vs FSC-H), then APC (BrdU) vs 7-AAD 
(DNA).   
 
Left ventricle intracardiac injection xenograft model of prostate cancer metastasis.      
Stable shRNA infected PC3GFP (1 x 106) or Du145GFP (2 x 105) prostate cancer cells were 
suspended in 100 µl of PBS and injected into male CB.17. SCID mice (6-8 weeks of age: 
Charles River Labs) by left ventricle intracardiac injection. For analysis of metastasis free 
survival, bioluminescence images were acquired after injection of luciferin twice weekly 
using a PerkinElmer IVIS 2000 system. Animals that had a large portion of the signal in 
the lungs (indicative of a right ventricle injection) were removed from analysis a priori. 
After removing mice that had a right ventricular injections or did not survive the 
procedure, the following numbers of animals were analyzed; PC3 shControl; 6, PC3 
shMER; 7, Du145 shControl; 20, and Du145 shMER; 18. Time to metastasis formation 
visible by bioluminescence (or death in rare cases) was then determined from the images. 
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The data was analyzed by Kaplan-Meier analysis. For analysis of transit to the bone 
marrow, different mice, 5 mice per group, were sacrificed 24 hours after tumor cell 
injection, and their pelvis, femora and tibiae were harvested. The bones were crushed 
with a mortar and pestle and strained to remove debris. All steps used PBS buffer with 
2% FBS unless otherwise noted. Cells were first depleted of mouse cells with a Mouse 
Cell Depletion Kit magnetic labeling system (Miltenyi Biotec # 130-104-694) and anti-
Biotin MicroBeads and an AutoMACS machine (Miltenyi Biotec). The enriched cells 
were incubated with an APC-Cy7 conjugated anti-HLA-ABC antibody (BioLegend 
#311426) and a PerCP-Cy5.5 conjugated anti-mouse lineage cocktail (CD3e, CD11b, 
B220, Ter-119, Ly-6G and Ly-6C) (BD Biosciences #561317), for an hour at 4°C, 
washed and resuspended in PBS with 2% FBS, 2 mM EDTA and 0.5 µg/ml DAPI. 
Thereafter, the percentage of disseminated prostate cancer cells (DTCs) was determined 
by gating on single, viable, lineage negative, HLA+ cells with a FACSAria IIu flow 
cytometer. Mice injected with PBS rather than PCa cells were used as a negative control 
for flow cytometry. Data represents 3 independent experiments. 
 
Prostate cancer subcutaneous tumor model. 
One million prostate cancer cells suspended in 50 µl complete media were mixed with an 
equal volume of cold collagen solution and then slowly injected under the skin of the 
back of SCID mice; 5 mice per group. Bioluminescence images were acquired weekly. 
Animals were sacrificed before tumors grew to 1 cm3. All experimental procedures were 
approved by the University of Michigan Committee for the Use and Care of Animals. 
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Prostate Cancer Cell Viability / MTS Assay 
Prostate cancer cells were seeded at 2000 cells per well in 96 well plates and rested for 
one day in 10% FCS RPMI media. The media was subsequently changed to the indicated 
serum concentrations and the cells were cultured for an additional 3 days. The total viable 
cell number was then assayed with the Cell Titer Aqueous One Solution MTS 
Proliferation Assay System (Promega #G3580) by absorbance at 490 nm. Data represent 
means of three independent experiments. 
 
Statistical analyses 
The type I error rate (α) was set to 0.05 for all analyses. Two-sample, two-tailed 
Student’s t-tests were used to compare means of two groups. One-way repeated measures 
analysis of variance (ANOVA) with Bonferroni post-hoc testing was used for data 
normalized to housekeeping genes (blots and PCR). Standard one-way ANOVA with 
Tukey’s Honest Significant Difference post-hoc testing was used for multiple 
comparisons in other experiments. The Log-rank test was used for Kaplan-Meier survival 
analyses. Growth curves for subcutaneous tumors were analyzed with a mixed design 
(split plot) ANOVA with repeated measures. All analyses were conducted with SPSS 
software, except for t-tests, which were performed in Microsoft Excel.  
 
RESULTS 
 
MERTK knockdown causes dormancy associated changes in MAPK activity and 
p27 expression.  
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To study the importance of TAM signaling on dormancy, each TAM receptor was stably 
knocked down with shRNA in PC3, Du145 and C4-2B prostate cancer cell lines. Protein 
expression of each receptor was decreased by at least 80% (Figure S1). A decreased ratio 
of P-Erk 1/2 to P-p38 MAPK marks cellular dormancy in prostate and other 
cancers(Kobayashi, Okuda et al. 2011, Bragado, Estrada et al. 2013, Chery, Lam et al. 
2014). Therefore, we first examined P-Erk1/2 and P-p38 levels in PC3 cells with each of 
the TAM receptors knocked down. The ratio of P-Erk 1/2 to P-p38 was significantly 
decreased in serum starved MERTK knockdown cells, but not in TYRO3 or AXL 
knockdown cells (Figure 1A and 1B). Similarly, the cell cycle inhibitor p27 was also 
previously found to be a dormancy marker(Kobayashi, Okuda et al. 2011, Bragado, 
Estrada et al. 2013). In agreement with the Erk and p38 data, we found higher basal p27 
protein expression in the MERTK knockdown cells (Figure 1C and 1D). These data are 
consistent with a dormant phenotype in prostate cancer cells as a result of chronically 
reduced expression of MERTK.  
 
MERTK knockdown causes expression of dormancy and pluripotency associated 
transcription factors 
 
Transcription factors first studied in embryonic stem cells have been found to promote 
cancer dormancy(Sosa, Parikh et al. 2015). Therefore, we determined the basal 
expression level of three of these transcription factors in PC3 cells with each of the TAM 
receptors knocked down by shRNA. In parallel with the MAPK and p27 data, we saw 
marked upregulation of SOX2 message and protein in shMER but not shAXL or 
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shTYRO3 cells (Figure 2A and 2B). Similarly, we also observed increased expression of 
SOX2 in shMER C4-2B cells (Figure 2A). We also observed increased NR2F1 and 
NANOG mRNA in shMER but not shAXL or shTYRO3 cells (Figure 2C and 2D). 
Because of the possibility of off target effects of shRNAs, we performed analogous 
studies with siRNA rather than shRNA and found that a siRNA targeting MERTK 
increased expression of SOX2 and NANOG in PC3 and C4-2B cells.    
 
MERTK knockdown induces cell cycle changes associated with cellular dormancy.  
 
Cellular dormancy and decreased Erk 1/2 activity are also characterized by arrest in the 
G1 and G0 phases of the cell cycle(Aguirre-Ghiso, Ossowski et al. 2004). Therefore, we 
compared cell cycle characteristics of TAM receptor knockdown PC3 cells cultured in 
0.1% serum using flow cytometry to detect antibody labeled pulsed bromodeoxyuridine 
(BrdU) incorporated into DNA and 7-AAD to quantify total DNA content. This assay 
identifies BrdU positive cells as S-phase, less than 2n DNA as apoptotic or necrotic cells, 
2n BrdU negative cells as G1 and G0 phases, 4n BrdU negative cells as G2 and M phases 
and cells with > 4n DNA as polyploid (Figure 3A). In agreement with our other data, 
MERTK knockdown cells showed a pattern consistent with dormancy, with a higher 
percentage of cells in G0/G1 and lower percentage in G2/M compared to control (Figure 
3B). Curiously, TYRO3 knockdown cells showed the opposite pattern with fewer cells in 
G0/G1 and more cells in the G2 and M phases. We did not convincingly see other 
analogous results for TYRO3 in our other experiments. We did not see differences 
between the different TAM knockdown cells in the percentage of cells in S-phase but 
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note that there are very few cells in S phase in this study because of the low serum 
conditions. However, we did observe a reduction in the sub-G0 (apoptotic and necrotic) 
population in the shMER cells. Further, western blots showed decreased levels of cleaved 
Caspase-9 in the shMER cells, thus suggesting that this reduced sub-G0 population 
represented reduced apoptosis. There is precedence in the literature for correlation of 
reduced apoptosis with a dormant phenotype(Aguirre-Ghiso, Ossowski et al. 2004). 
Further, p38 stimulated cellular dormancy and reduced apoptosis have been proposed to 
be adaptive responses to allow DTCs to survive when conditions are not conducive to 
growth(Ranganathan, Adam et al. 2006).     
 
Depletion of MERTK increases metastasis free survival in vivo 
 
We next tested the importance for MERTK for dorman y escape in vivo. GFP and 
luciferase labeled control shRNA or MERTK shRNA PC3 or Du145 PCa cells were 
injected in the left ventricle of SCID mice and time to metastases visible by 
bioluminescence imaging, or death in rare cases, was evaluated with Kaplan-Meier 
analysis (Figure 4A). Metastases are primarily to bone with both cell lines. Metastasis 
free survival in this model is established in the literature as a measure of dormancy 
(Kobayashi, Okuda et al. 2011). In agreement with the in vitro data, metastasis free 
survival was prolonged in mice injected with shMER PC3 cells relative to control cells 
(Figure 4B, top left). With Du145 cells, the increase in metastasis free survival with 
MERTK knockdown was small and not statistically significant (Figure 4B, lower left). 
However, we noted that shMER Du145 cells appeared to develop metastases to the head 
Au
tho
r M
an
us
cri
pt
more slowly, which approached statistical significance (Figure 4B, lower right). Time to 
cranial metastases was again significantly different with PC3 cells. A defect in transit to 
the bone marrow could also explain delayed metastasis formation but would not involve 
dormancy escape. Therefore, in separate experiments, we used flow cytometry to 
quantify the percentage of control or shMER PC3 cells in marrow one day after injection 
and found no difference (Figure 4C-D). This further supports the conclusion that 
MERTK is selectively important for dormancy escape rather than transit to the bone 
marrow in this model.  
 
MERTK knockdown does not decrease prostate cancer growth in vitro or at a 
subcutaneous site in vivo. 
 
We hypothesized that the role of MERTK was somewhat specific to cellular dormancy 
and therefore it should not greatly affect overall cellular growth in vitro or in vivo at a site 
not dependent on the usual microenvironment, such as a subcutaneous site with an 
artificial extracellular matrix. Indeed, other groups who have derived dormant and 
tumorigenic cancer cell lines have observed similar growth in culture(Bragado, Estrada et 
al. 2013, Sharma, Xing et al. 2016). In agreement with these expectations, we saw no 
difference in subcutaneous growth in vivo between control and shMER PC3 cells and saw 
slightly higher growth of Du145 shMER cells compared to control (figure 5A). Similarly, 
we saw no significant differences in relative cell number, as measured by MTS assay, 
between any of the TAM shRNA knockdowns in PC3, Du145 and C4-2B cells cultured 
for 3 days in 0.1%, 1% or 10% serum (Figure 5B). The Du145 shMER cells trended 
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towards higher relative cell number but did not reach statistical significance after multiple 
comparison testing.     
 
Cell cycle changes of MERTK knockdown are MAP kinase dependent. 
 
Because of the well-established role of MAP kinases in regulation of cancer cellular 
dormancy, we investigated if p38 was required for the dormancy associated cell cycle 
changes induced by knockdown of MERTK. In appreciation of the known role of 
epigenetic changes in dormancy regulation and the time period required for these changes 
to occur, we cultured control and MERTK shRNA PC3 and Du145 cells with p38 
inhibitor SB203580 or 0.05% DMSO solvent control for two weeks before performing 
experiments(Sosa, Parikh et al. 2015). The expected compensatory increase in P-p38 in 
response to p38 active site inhibition was observed by Western blot (Figure S2A). We 
again observed an increased percentage of G0/G1 and decreased percentage of G2/M 
cells with MERTK knockdown both in PC3 and Du145 cells (Figure 6). This change 
induced by MERTK knockdown was completely reversed by p38 inhibition, thus 
showing involvement of MAP kinases. Similarly, we also observed a increased 
percentage of Ki67 negative cells (non-cycling) with MERTK knockdown in PC3 cells, 
which was also reversed by p38 inhibition (Figure S2C). Curiously, we did not observe 
reversal of shMER induced p27 upregulation with p38 inhibition (Figure S2B). This 
suggests that not all of the effects of MERTK knockdown are MAP kinase dependent.   
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MERTK knockdown induces dormancy associated changes in histone H3 
methylation by a MAP kinase dependent mechanism.   
 
Lastly, we used flow cytometry with specific antibodies to determine the effect of shRNA 
knockdown in PC3 cells of each of the TAM receptors on histone H3 tri-methylated 
lysine 9 (H3 K9 me3) and histone H3 tri-methylated lysine 27 (H3 K27 me3). Both of 
these histone marks are increased in dormant cells(Sosa, Parikh et al. 2015). Because the 
majority of cells were positive, we gated on the negative and dim populations rather than 
the positive population (Figure 7A). We observed the expected dormancy associated 
change in H3 K9me3, and a trend towards significance for H3 K27me3 with MERTK 
knockdown but no significant differences for AXL or TYRO3 knockdown (Figure 7B). 
In cells treated with the p38 inhibitor SB203580 or solvent control, we saw significant 
dormancy associated changes with MERTK knockdown, which were partially reversed 
by p38 inhibition (Figure 7C). DISCUSSION 
 
Overall, these studies implicate MERTK in prostate cancer dormancy escape through a 
MAP kinase dependent mechanism linked to transcriptional and epigenetic regulation. 
Knockdown of MERTK consistently induced the changes expected for dormant cells; a 
decreased ratio of P-Erk to P-p38, increased p27 expression, expression of dormancy and 
pluripotency associated transcription factors, and G0/G1 arrest. Further, these findings 
translated to an increased metastasis free survival in vivo. This identifies MERTK as 
being important for the process whereby one or a few cancer cells progress to a small 
tumor (i.e. escape from cellular dormancy). As expected, MERTK knockdown did not 
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inhibit growth in culture or growth of subcutaneous tumors implanted in an artificial 
matrix. This lack of a general growth inhibitory effect of MERTK knockdown suggests 
specificity for dormancy regulation in bone and a requirement for a signal from the 
microenvironment rather than dysregulation of multiple cellular processes.  
 
Our data do not identify which signal(s) from the microenvironment interact with 
MERTK to regulate dormancy. The four other TAM receptor ligands, other than GAS6 
(Tulp1, Tubby, Galectin 3 and Protein S), may also play a role. Although not a MERTK 
ligand, retinoic acid may be indirectly involved as well because it has been shown to 
stimulate cancer dormancy through NR2F1 and also interacts indirectly with MERTK in 
immune cells(Garabuczi, Sarang et al. 2015, Sosa, Parikh et al. 2015). Because no 
recombinant protein or other treatment other than low serum conditions was required for 
our observed in vitro effects, knockdown of MERTK may have caused epigenetic 
reprogramming of the cells as a result of chronic alterations in signaling from autocrine 
TAM receptor ligands. Prostate cancer cells are known to express MERTK ligands GAS6 
and PROS1 (Protein S)(Jung, Decker et al. 2016, Ning, Zhong et al. 2016). The observed 
changes in histone H3 methylation also suggests that part of the effects of MERTK may 
be due to epigenetic reprogramming rather than through a more immediate response to 
ligands.  
 
Previously, we examined the expression of TYRO3 and AXL, but not MERTK in 
disseminated tumor cells (DTCs) vs prostate cancer primary tumors and gross 
metastases(Taichman, Patel et al. 2013). We reported higher expression of AXL in DTCs 
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and higher expression of TYRO3 in primary tumors and gross metastases. Thus, we 
hypothesized that AXL might be important for maintenance of dormancy and TYRO3 
might be important for escape from dormancy or growth of a gross tumor. In retrospect, it 
would have been useful in include MERTK in these studies. Our most recent work, 
currently in press, confirms the earlier hypothesis regarding AXL and shows that AXL is 
required for TGF-β2 induced prostate cancer dormancy(Yumoto 2016). However, prior to 
the current work, the contribution of MERTK to prostate cancer dormancy remained 
completely unclear. Here, we took an unbiased approach and were consistently guided by 
the data to focus on MERTK. However, our data does not rule out contributions from 
AXL or TYRO3 in stimulation of dormancy escape. For example, the percent knockdown 
might have been insufficient to observe effects with shAXL or shTYRO3.  
 
We recently reported a role for MERTK in formation of prostate cancer stem-like cells 
(CSCs)(Jung, Decker et al. 2016, Shiozawa, Berry et al. 2016). However, the 
proliferative rate of CSCs was not examined in these studies and other literature reports 
that CSCs can be either slowly or rapidly cycling(Sharma, Xing et al. 2016, Takeishi and 
Nakayama 2016). Additionally, others identified MERTK in an unbiased screen of over 
100 kinases as a stimulator of prostate cancer metastasis. Therefore, our data showing a 
new role for MERTK in dormancy escape combined with the other studies implicating 
MERTK in CSC formation and metastasis, suggests that MERTK plays a role in prostate 
cancer progression by regulating several processes.    
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In summary, we are beginning to understand the roles of the TAM kinases in prostate 
cancer dormancy regulation. AXL plays a role in dormancy maintenance through TGF-β2 
and microenvironment dependent effects. The role of TYRO3 remains less clear. 
Conversely this study provides the first evidence that MERTK stimulates prostate cancer 
dormancy escape. Our studies with a p38 inhibitor show MAP kinases are required for 
MERTK to stimulate dormancy escape. Furthermore, MERTK causes changes observed 
in histone H3 methylation, pluripotency associated transcription factors and cell cycle 
regulatory proteins observed in dormancy regulation of other cancers (Figure 8). Thus, 
MERTK appears to reprogram disseminated tumor cells to grow rather than remain 
dormant. This understanding of the role of MERTK should inform future studies of 
prostate cancer dormancy and may provide a therapeutic target for prevention of 
recurrence. 
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FIGURE LEGENDS 
 
Figure 1. TAM receptor knockdown and dormancy associated pathways in prostate 
cancer cells. A, Representative Western blots of PC3 cells with each of the TAM 
receptors knocked down by shRNA probed for phosphorylated or total p38 and Erk 1/2 or 
housekeeping genes. B, Quantification of the samples in panel A for P-Erk, P-p38 or the 
ratio of P-Erk to P-p38 relative to the values for the scrambled shRNA control and 
normalized to the housekeeping genes. C, Representative Western blot for p27 of the 
same cells. D, Quantification of the data in C. All data is presented normalized to control. 
Error bars represent mean ± SEM. * Represents p < 0.05 compared to shRNA control 
cells. 
 
Figure 2. TAM receptor knockdown and expression of dormancy and pluripotency 
associated transcription factors. A, PC3 cells with each of the TAM receptors knocked 
down by shRNA or C4-2B cells with MERTK knocked down, analyzed for SOX2 
expression by qPCR. B, Representative SOX2 Western blot of shControl and shMER 
PC3 cells. C, D, PC3 TAM receptor shRNA cells with expression of NR2F1 or NANOG 
respectively, quantified by qPCR. E, PC3 cells with MerTK knocked down by siRNA 
and quantified for expression of SOX2 and NANOG by qPCR. F, C4-2B cells with 
MERTK knocked down by siRNA and quantified for expression of SOX2 and NANOG 
by qPCR. All data is presented normalized to control. Error bars represent mean ± SEM. 
* Represents p < 0.05 compared to shRNA or siRNA control cells. 
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Figure 3. Cell cycle analysis of TAM receptor knockdown PC3 cells by flow cytometry 
with BrdU and total DNA labeling. A, Example flow plots for each cell type. Top: 
histograms of total DNA content labeled with7-AAD. Bottom: BrdU vs. total DNA plots. 
The significance of each population is as follows: < 2n DNA and BrdU negative; Sub-G0 
(apoptotic and necrotic), 2n DNA and BrdU negative; G0 and G1 phases, 4n DNA and 
BrdU negative; G2 and M phases. BrdU positive; S phase, > 4n DNA; polyploid cells. B, 
Quantification of the above cell cycle data. The table lists p-values for each cell type 
compared to control with significant comparisons marked with an asterisk. Error bars are 
shown for the G0G1 and G2M populations and represent mean ± SEM. * Represents p < 
0.05 compared to shRNA control cells. C, Western blots for total caspase-9 to verify the 
changes in Sub-G0 cells observed by flow cytometry.    
 
Figure 4. MERTK knockdown and metastasis free survival in a prostate cancer left 
ventricle injection xenograft model. A, Experimental design. B, Kaplan-Meier analysis of 
time to formation of metastases visible by bioluminescence imaging or death in mice 
injected with luciferase labeled control or shMER PC3 or Du145 cells. Left panels: 
metastases to any site. Right panels: cranial metastases only.* Indicates p < 0.05 vs 
control cells. C, Strategy for quantification of the percentage of DTCs in mouse bone 
marrow by flow cytometry after first depleting the number of mouse cells with 
immunomagnetic beads. D, Comparison of the percentage of DTCs in mouse bone 
marrow in control vs. shMER PC3 cells one day after intracardiac injection. Error bars 
represent mean ± standard error.       
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Figure 5. Effect of MERTK knockdown on growth of prostate cancer cells in culture and 
in subcutaneous tumors. A, Subcutaneous tumor growth of control or shMER PC3 or 
Du145 cells as measured by bioluminescence imaging. B, Relative cell number 
quantified by XTT assay after 3 days of culture in 10%, 1% or 0.1% serum for PC3, 
Du145 and C4-2B cells with each of the TAM receptors knocked down. Data are 
presented as mean ± SEM. No pairwise comparisons were statistically significant.   
 
Figure 6. Reversal of the shMER cell cycle phenotype with long term p38 inhibition. A, 
Control or shMER PC3 cells cultured with 5 µM SB203580 or 0.05% DMSO solvent 
control for 14 days in 10% serum and 3 days in 0.1% serum followed by cell cycle 
analysis with total DNA and BrdU labeling as described for figure 3. Top: Total DNA 
flow cytometry histograms. Bottom: quantified data. Error bars are shown for the G0G1 
and G2M populations and represent mean ± SEM. * Represents p < 0.05 for comparisons 
of interest. B, Cell cycle analysis as above of Du145 cells grown for 17 days in 10% 
serum with or without SB203580.  
 
Figure 7. Presence and MAP kinase dependence of dormancy associated histone H3 post 
translational modifications in TAM receptor knockdown prostate cancer cells. A, 
Example plots for percentage of cells negative or dim for histone H3 tri-methylated 
lysine 9 and tri-methylated lysine 27 evaluated by flow cytometry. B, Percent of PC3 
cells with each TAM receptor knocked down by shRNA negative for each histone H3 tri-
methylation. C, Control or shMER PC3 cells cultured for 14 days with or without p38 
inhibitor SB203580 (as in figure 6) negative or dim for tri-methylated histone H3 lysine 9 
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or lysine 27. Error bars represent mean ± SEM. * Represents p < 0.05 compared to 
control for panel B, or for comparisons of interest for panel C.   
 
Figure 8. Results summary 
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